EyePoint Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 2, 2023
26 Julho 2023 - 8:00AM
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed
to developing and commercializing therapeutics to improve the lives
of patients with serious eye disorders, today announced it will
host a conference call and live webcast at 8:30 a.m. ET on
Wednesday, August 2, 2023 to report its second quarter 2023
financial results and highlight recent corporate developments.
To access the live conference call, please
register using the audio conference link:
https://register.vevent.com/register/BI1f9c401d832f439690f47dc2454e01d6.
A live audio webcast of the event can be accessed via the Investors
section of the Company website at www.eyepointpharma.com. A webcast
replay will also be available on the corporate website at the
conclusion of the call.
About EyePoint
Pharmaceuticals
EyePoint Pharmaceuticals (NASDAQ: EYPT) is a
company committed to developing and commercializing therapeutics to
help improve the lives of patients with serious eye disorders. The
Company's pipeline leverages its proprietary erodible Durasert E™
technology for sustained intraocular drug delivery including
EYP-1901, an investigational sustained delivery intravitreal
anti-VEGF treatment currently in Phase 2 clinical trials. The
proven Durasert® drug delivery platform has been safely
administered to thousands of patients' eyes across four U.S. FDA
approved products. EyePoint Pharmaceuticals is headquartered in
Watertown, Massachusetts. For more information visit
www.eyepointpharma.com.
Investors:Christina
TartagliaStern IRDirect:
212-698-8700christina.tartaglia@sternir.com
Media ContactAmy PhillipsGreen
Room CommunicationsDirect:
412-327-9499aphillips@greenroompr.com
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024